Journal
JOURNAL OF CONTROLLED RELEASE
Volume 113, Issue 2, Pages 155-163Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jconrel.2006.04.009
Keywords
cancer; gene therapy; cationic liposome; lipoplex; targeted; DNA
Ask authors/readers for more resources
Targeted gene therapy is essential if cancer treatment is to become a reality with this form of therapy. In the past few years, cationic liposomes, discovered 2 decades ago, and at present, the most commonly used class of transfection reagents, have been tested in various clinical trials for diseases not restricted to cancer. They have been shown to be selective for tumour vascular endothelial cells raising hopes for antiangiogenic and antivascular therapies. They are also capable of being selectively delivered to the lungs and liver when administered intravenously. These vesicles are also being targeted to the tumour in various parts of the body by using advanced liposomal systems such as antibody-antigen and ligandreceptor combinations. This review looks at the state of play in this rapidly growing field. (c) 2006 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available